Category: evidence-based medicine

More Workings of an Evidence-Based Genomic Panel: Modernizing the Evidence Review Process

EGAPP logo

The independent EGAPP working group (EWG) held its 25th meeting on September 10-11, 2012 at the CDC campus in Atlanta. Highlights included: Three EWG recommendation statements on the validity and utility of genetic tests are pending publication on: KRAS, BRAF and other markers involved in EGFR signaling, which are used to inform choice of therapies for Read More >

Posted on by W. David Dotson and Michael P. Douglas, Office of Public Health Genomics, Centers for Disease Control and PreventionLeave a commentTags ,

Evidence Matters in Genomic Medicine- Round 2: Integrating Cancer Genomic Tests

stacked boxes with lettering

  In a previous blog, CDC’s Office of Public Health Genomics announced a list of health-related genomic tests and applications, stratified into three tiers according to the availability of scientific evidence and evidence-based recommendations as a result of systematic reviews.  The list is intended to promote information exchange and dialogue among researchers, providers, policy makers, and Read More >

Posted on by Michael P. Douglas and W. David Dotson, Office of Public Health Genomics, Centers for Disease Control and Prevention1 CommentTags , , ,

Workings of an Evidence-Based Genomic Panel

EGAPP logo

  Synopsis of the 24th Meeting of the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group The EGAPP working group (EWG) has held 24 meetings in the 7 years since they were first convened; the latest EGAPP meeting was May 7-8, 2012 on the campus of CDC in Atlanta. Since it is Read More >

Posted on by W. David Dotson and Michael P. Douglas, Office of Public Health Genomics, Centers for Disease Control and PreventionLeave a commentTags , , , , , ,

Evidence Matters in Genomic Medicine

EGAPP logo

A new IOM report makes recommendations that aim to ensure that progress in omics-based test development is grounded in sound scientific evidence and is reproducible, resulting in improved health care and continued public trust in research.  Another new IOM roundtable workshop report discussed the differences in evidence required for clinical use, regulatory oversight, guideline inclusion, coverage, Read More >

Posted on by Michael P. Douglas and W. David Dotson, Office of Public Health Genomics, Centers for Disease Control and Prevention1 CommentTags , ,